Skip to main content
PMC home page
Neurotherapeutics logoLink to Neurotherapeutics
. 2007 Jan;4(1):126–129. doi: 10.1016/j.nurt.2006.11.001

Talampanel

John F Howes 1, Cynthia Bell 2,✉
PMCID: PMC7479696  PMID: 17199027

Summary

Talampanel is a novel anticonvulsant that acts as an allosteric inhibitor of the AMPA receptor. Talampanel has a broad spectrum of action in animal models of epilepsy and neuroprotection. Clinical experience to date has been able to show effectiveness in reduction of seizures in patients with refractory partial seizures.

Key Words: AMPA, epilepsy, glutamate, neuroprotection, talampanel

References

  • 1.Ueda Y, Doi T, Tokumaru J, Willmore LJ. Effect of zonisamide on molecular regulation of glutamate and GABA transporter proteins during epileptogenesis in rats with hippocampal seizures. Brain Res Mol Brain Res. 2003;116:1–6. doi: 10.1016/S0169-328X(03)00183-9. [DOI] [PubMed] [Google Scholar]
  • 2.Meldrum BS, Akbar MT, Chapman AG. Glutamate receptors and transporters in genetic and acquired models of epilepsy. Epilepsy Res. 1999;36:189–204. doi: 10.1016/S0920-1211(99)00051-0. [DOI] [PubMed] [Google Scholar]
  • 3.Rogawski MA, Donevan SD. AMPA receptors in epilepsy and as targets for antiepileptic drugs. Adv Neurol. 1999;79:947–963. [PubMed] [Google Scholar]
  • 4.Lodge D, Bond A, O’Neill MJ, Hicks CA, Jones MG. Stereose-lective effects-of 2,3-benzodiazepinesin vivo: electrophysiology and neuroprotection studies. Neuropharmacology. 1996;35:1681–1688. doi: 10.1016/S0028-3908(96)00155-4. [DOI] [PubMed] [Google Scholar]
  • 5.Solyom S, Tamawa I. Non-competitive AMPA antagonist of 2,3-benzodiazepine type. Curr Pharm Des. 2002;8:913–919. doi: 10.2174/1381612024607081. [DOI] [PubMed] [Google Scholar]
  • 6.Szelenyi I, Horvath K, Howes JF, Mazarati AM. The treatment of epilepsy: future possibilities. Drugs of the Future. 2003;28:925–936. doi: 10.1358/dof.2003.028.09.857380. [DOI] [Google Scholar]
  • 7.Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ. The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol. 1995;281:319–326. doi: 10.1016/0014-2999(95)00266-N. [DOI] [PubMed] [Google Scholar]
  • 8.Borowicz KK, Zdzislaw K, Czuczwar SJ. The AMPA/kainite receptor antagonist, LY 300164, increases the anticonvulsant effects of diazepam. Naunyn Schmiedebergs Arch Pharmacol. 2000;361:629–635. doi: 10.1007/s002100000237. [DOI] [PubMed] [Google Scholar]
  • 9.Czuczwar SJ, Swiader M, Kuzniar H, Gasior M, Kleinrok Z. LY 300164, a novel antagonist of AMPA/kainite receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol. 1998;359:103–109. doi: 10.1016/S0014-2999(98)00632-3. [DOI] [PubMed] [Google Scholar]
  • 10.Swiader M, Kuzniar H, Kleinrok Z, Czuczwar SJ. Influence of LY 300164, an AMPA/kainate receptor antagonist, upon the anticonvulsant action of antiepileptic drugs against aminophylline-induced seizures in mice. Pol J Pharmacol. 2003;55:103–107. [PubMed] [Google Scholar]
  • 11.Jakus R, Graf M, Ando RD, et al. Effect of two noncompetitive AMPA receptor antagonists GYKI 52466 and GYKI 53405 on vigilance, behavior and spike-wave discharges in a genetic rat model of absence epilepsy. Brain Res. 2004;1008:236–244. doi: 10.1016/j.brainres.2004.01.087. [DOI] [PubMed] [Google Scholar]
  • 12.Erdõ F, Berzsenyi P, Andrási F. The AMPA-antagonist talampanel is neuroprotective in rodent models of focal cerebral ischemia. Brain Res Bull. 2005;66:43–49. doi: 10.1016/j.brainresbull.2005.03.012. [DOI] [PubMed] [Google Scholar]
  • 13.Erdõ F, Berzsenyi P, Német L, Andrási F. Talampanel improves the functional deficit after transient focal cerebral ischemia in rats: a 30-day follow up study. Brain Res Bull. 2006;68:269–276. doi: 10.1016/j.brainresbull.2005.08.018. [DOI] [PubMed] [Google Scholar]
  • 14.Szabados T, Gigler G, Gacsályi I, Gyertyán I, Lévay G. Comparison of anticonvulsive and acute neuroprotective activity of three 2,3-benzodiazepine compounds, GYKI 52466, GYKI 53405, and GYKI 53655. Brain Res Bull. 2001;55:387–391. doi: 10.1016/S0361-9230(01)00516-0. [DOI] [PubMed] [Google Scholar]
  • 15.Belayev L, Alonso OF, Liu Y, et al. Talampanel, a novel noncompetitive AMPA antagonist, is neuroprotective after traumatic brain injury in rats. J Neurotrauma. 2001;18:1031–1038. doi: 10.1089/08977150152693728. [DOI] [PubMed] [Google Scholar]
  • 16.Langan YM, Lucas R, Jewell H, et al. Talampanel, a new antiepileptic drug: single- and multiple-dose pharmacokinetics and initial 1-week experience in patients with chronic intractable epilepsy. Epilepsia. 2003;44:46–53. doi: 10.1046/j.1528-1157.2003.128902.x. [DOI] [PubMed] [Google Scholar]
  • 17.Buchwald P, Juhász A, Bell C, et al. Influence of the N-acetylation polymorphism on the metabolism of talampanel: an investigation in fasted and fed subjects genotyped for NAT2 variants. Pharmazie. 2006;61:125–134. [PubMed] [Google Scholar]
  • 18.Buchwald P, Juhász A, Bell C, Pátfulusi M, Howes J, Bodor N. Unified pharmacogenetics-based parent-metabolite pharmacokinetic model incorporating acetylation polymorphism for talampanel in humans. J Pharmacokinet Pharmacodyn. 2005;32:377–400. doi: 10.1007/s10928-005-0001-y. [DOI] [PubMed] [Google Scholar]
  • 19.Gidal BE, Ramsay E, Howes J, Bell C. Evaluation of the pharmacokinetic interaction between valproic acid and talampanel in healthy volunteers. Presented at the American Epilepsy Society Annual Meeting Submission Program; April 2005; Miami Beach, FL.
  • 20.Chappell AS, Sander JW, Brodie MJ, et al. A crossover, add-on trial of talampanel in patients with refractory partial seizures. Neurology. 2002;58:1680–1682. doi: 10.1212/wnl.58.11.1680. [DOI] [PubMed] [Google Scholar]
  • 21.Fetell MR, Ramsay RE, Bell C, Tang S. Efficacy of the AMPA antagonist talampanel in refractory partial epilepsy. J Neurol Sci 2005;(suppl 1):A238. Abstract.
  • 22.Nagasawa H, Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model, of middle cerebral artery occlusion. Stroke. 1989;20:1037–1043. doi: 10.1161/01.str.20.8.1037. [DOI] [PubMed] [Google Scholar]
  • 23.Erdõ F, Trapp T, Mies G, Hossmann KA. Immunohistochemical analysis of protein expression after middle cerebral artery occlusion in mice. Acta Neuropathol. 2004;107:127–136. doi: 10.1007/s00401-003-0789-8. [DOI] [PubMed] [Google Scholar]
  • 24.Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD. Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol. 1985;17:497–504. doi: 10.1002/ana.410170513. [DOI] [PubMed] [Google Scholar]

Articles from Neurotherapeutics are provided here courtesy of Elsevier

RESOURCES